Studies in animal models have shown that IgG1 monoclonal antibody, an anti-TGF-βRII (LY3022859) blocks the binding of TGF-β to ectodomain of TGF-βRII which results in significant decrease in tumor growth and metastasis (Zhong et al., 2010). This evidence concerns the gene TGFB1 and neoplasm.